IRTC IRhythm Technologies Inc.

iRhythm® Technologies Announces Changes to Its Board of Directors

iRhythm® Technologies Announces Changes to Its Board of Directors

Karen Ling Appointed to the Board; Raymond Scott to Retire

SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC) (“iRhythm”), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the appointment of Karen Ling, an experienced HR leader, to its Board of Directors effective November 1, 2021. Ms. Ling was appointed as a Class 1 Director. The company also announced the retirement of Raymond Scott from the Board, effective November 1, 2021. Mr. Scott joined the iRhythm Board in 2013.

“On behalf of the entire iRhythm team, I am pleased to welcome Karen to our Board of Directors,” said Quentin Blackford, iRhythm President and CEO. “Karen is a renowned HR leader in the healthcare and insurance industries and brings a wealth of experience and unique perspectives to iRhythm. Karen will play an important role in guiding iRhythm’s organizational goals and strategies as the business continues to scale on a global basis. We are looking forward to Karen’s contributions.”

“I am honored to join the iRhythm Board,” commented Ms. Ling on her appointment. “iRhythm is a special company that has proven its ability to innovate and deliver a highly valuable technology and service to patients and providers. I am looking forward to contributing my expertise and counsel as iRhythm continues to scale its operations and expand its market opportunities.”

On Mr. Scott’s departure from the Board, Abhi Talwalkar, Chairman of the iRhythm Board, commented, “We would like to thank Ray for his service over the past eight years. Ray’s expertise helped guide iRhythm through a period of tremendous growth and Ray’s contributions during this time were immense. We wish Ray all the best in his future endeavors.”

About Karen Ling

Ms. Ling recently retired from her role as Executive Vice President and Chief Human Resources Officer for American International Group, Inc. (“AIG”), a position she had held since July 2019. In this role, Ms. Ling oversaw all aspects of human capital management, including talent acquisition, training, development, compensation and benefits, and diversity, equity and inclusion. From 2014 until joining AIG, Ms. Ling served as Executive Vice President and Chief Human Resources Officer at Allergan plc., a pharmaceutical company. In this capacity, Ms. Ling developed and oversaw a global HR strategy during a period of transition that included successfully launching new company-wide HR and cultural initiatives. Previously Ms. Ling was Senior Vice President, Human Resources for Merck & Co., Inc.’s Global Human Health and Consumer Care businesses worldwide. Prior to Merck, she was Group Vice President, Global Compensation & Benefits at Schering-Plough. Ms. Ling also spent 14 years at Wyeth in various positions of increasing responsibility developing HR strategies for business units and working in Wyeth’s Labor & Employment Department. Prior to Wyeth, Ms. Ling practiced law in Boston, Massachusetts.

Ms. Ling holds a J.D. from Boston University School of Law and a B.A. in Economics from Yale University.

About iRhythm Technologies, Inc.

iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements relating to growth expectations and personnel matters. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission on Forms 10-K and 10-Q. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

Investor Relations Contact

Leigh Salvo

(415) 937-5404





Media Contact

Morgan Mathis

(310) 528-6306



EN
12/10/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IRhythm Technologies Inc.

 PRESS RELEASE

iRhythm Holdings to Report Fourth Quarter and Full Year 2025 Financial...

iRhythm Holdings to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 SAN FRANCISCO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the fourth quarter and full year 2025 after the close of trading on Thursday, February 19, 2026. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and...

 PRESS RELEASE

iRhythm Technologies, Inc. Shares Preliminary Fourth Quarter 2025 High...

iRhythm Technologies, Inc. Shares Preliminary Fourth Quarter 2025 Highlights and Business Update at the 44th Annual J.P. Morgan Healthcare Conference SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 44th Annual J.P. Morgan Healthcare Conference. Recent Operational Highlights and Financial Outlook Anticipate full year 2025 revenue to exc...

 PRESS RELEASE

iRhythm Technologies to Present at the 44th Annual J.P. Morgan Healthc...

iRhythm Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference SAN FRANCISCO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference. iRhythm’s management is scheduled to present on Monday, January 12, 2026, at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on...

 PRESS RELEASE

New Data at the Asia Pacific Heart Rhythm Society (APHRS) 2025 Highlig...

New Data at the Asia Pacific Heart Rhythm Society (APHRS) 2025 Highlight the Performance of iRhythm’s Zio Long-Term Continuous Monitoring in an Asian Population iRhythm Technologies presented new data during the joint Asia Pacific Heart Rhythm Society (APHRS) and Japan Heart Rhythm Society (JHRS) scientific sessions.Large-scale analysis of more than 400,000 patients1 supports the consistency and generalizability of Zio long-term ECG monitoring (LTCM) performance across populations; median wear and analyzable time among patients identified as Asian (3.4% of the cohort) were comparable to tho...

 PRESS RELEASE

第18回アジア太平洋不整脈学会学術大会(APHRS2025)で発表された新たなデータにより アジア人集団におけるiRhythm社のZio長期...

第18回アジア太平洋不整脈学会学術大会(APHRS2025)で発表された新たなデータにより アジア人集団におけるiRhythm社のZio長期連続モニタリングの性能が明らかに iRhythm Technologies, Inc.は、アジア太平洋不整脈学会学術大会(APHRS2025)と第71回日本不整脈心電学会学術大会(JHRS2025)の合同学術集会において新しいデータを発表しました。40万人を超える患者を対象とした大規模解析 1 により、長期間の心電図(ECG)モニタリングの性能の一貫性と一般化可能性が裏付けられました。アジア人患者(コホートの3.4%)における中央値の装着時間および解析可能時間は非アジア人患者と同等であり、この結果は既発表のCAMELOT研究2 およびAVALON研究3 で報告されたZio LTCMの性能と一致していました。 サンフランシスコ, Nov. 21, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC) は2025年11月12日から15日まで日本・横浜で開催された第18回アジア太平洋不整脈学会(APHRS)/第71回日本不整脈心電学会学術大会(JHRS2025)合同学術集会において、口頭発表セッションで新たなデータを発表したと明らかにしました。 河田 宏医師の主導のもと、研究チームは米国の大規模患者コホートを対...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch